Apixaban
Venous Thromboembolism
Regeneron PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BBB
79/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 72/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Venous Thromboembolism cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
WARFARIN Northern Jiangsu People's Hospital | Phase 4 | A |
Aspirin Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 | BBB |
NADROPARIN Rijnstate Hospital | Phase 4 | BBB |
Rivaroxaban Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 | BBB |
Dalteparin Beijing Friendship Hospital | Phase 4 | BBB |
View all 28 →
Same molecule, other indications
Apixaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →